InspireMD, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that InspireMD, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $2.31M | Mar 28, 2016 |
| FY2015 | Dec 31, 2014 | $2.82M | Mar 28, 2016 |
| FY2014 | Dec 31, 2013 | $3.11M | Mar 12, 2015 |
| FY2014 | Jun 30, 2013 | $4.87M | Mar 12, 2015 |
| FY2014 | Jun 30, 2012 | $5.35M | Mar 12, 2015 |
| FY2011 | Dec 31, 2011 | $6.00M | Mar 13, 2012 |
| FY2011 | Dec 31, 2010 | $4.95M | Mar 13, 2012 |
| FY2011 | Dec 31, 2009 | $3.41M | Mar 13, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.98M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $7.01M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $6.21M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $5.17M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $4.50M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.49M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $3.72M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $3.60M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $2.76M | Feb 19, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.76M | Feb 13, 2018 |
| FY2017 | Dec 31, 2016 | $1.89M | Feb 13, 2018 |
| FY2016 | Dec 31, 2015 | $2.31M | Feb 16, 2017 |
| FY2015 | Dec 31, 2014 | $2.82M | Mar 28, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.65M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.51M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $1.81M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $1.12M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $754.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $83.0K | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $756.0K | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $995.0K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $585.0K | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $102.0K | Feb 13, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.79M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($32.01M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($19.92M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($18.49M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($14.92M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.54M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($10.04M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($7.24M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($8.44M) | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | ($8.46M) | Feb 13, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.61M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($33.50M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($21.14M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($18.71M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($14.72M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($10.38M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($9.82M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($7.61M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($8.23M) | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | ($7.65M) | Feb 13, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.00M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $13.63M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $7.98M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $7.81M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $5.16M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.23M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $2.95M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $1.54M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $1.28M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $1.29M | Feb 13, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.10M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($21.87M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($16.38M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($15.54M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($13.21M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($9.08M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($9.81M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($7.61M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($8.13M) | Feb 19, 2019 |
| FY2013 | Jun 30, 2013 | ($10.30M) | Sep 17, 2013 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.66M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.40M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $381.0K | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $473.0K | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $344.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $88.0K | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $284.0K | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $67.0K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $258.0K | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $49.0K | Feb 13, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.40M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $46.81M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $47.64M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $24.65M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $39.71M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $17.78M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $9.88M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $12.29M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $6.11M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $9.41M | Feb 13, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.20M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $10.72M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $8.14M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $7.26M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $6.18M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $5.61M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $4.50M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $3.53M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $3.11M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $5.37M | Feb 13, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.20M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $36.09M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $39.50M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $17.39M | Mar 12, 2025 |
| FY2023 | Dec 31, 2021 | $33.53M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $12.16M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $5.38M | Mar 7, 2022 |
| FY2020 | Dec 31, 2018 | $8.76M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $2.73M | Mar 10, 2020 |
| FY2018 | Dec 31, 2016 | $4.05M | Feb 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($302.29M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($253.51M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($221.50M) | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | ($201.59M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($183.09M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($168.18M) | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | ($157.63M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($147.59M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($140.35M) | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | ($131.91M) | Feb 13, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.94M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $18.92M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $9.64M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | $4.63M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $12.00M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $12.65M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | $5.51M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $9.38M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $3.71M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $7.52M | Feb 13, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $5.01M | Mar 28, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 5, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 43.53M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 26.61M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 21.84M | Mar 12, 2025 |
| FY2023 | Dec 31, 2022 | 8.33M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 8.30M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 3.28M | Mar 7, 2022 |
| FY2020 | Dec 31, 2019 | 3.92M | Mar 8, 2021 |
| FY2020 | Dec 31, 2018 | 38.40M | Mar 8, 2021 |
| FY2018 | Dec 31, 2017 | 1.48M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | 42,653 | Feb 13, 2018 |